All Posts

The Pre-Conflict Backdrop — A Sector in Recovery Before the conflict escalated, global healthcare investing was on an improving trajectory. Biotech had begun to emerge from a two-year slump in April 2025, entering a near-historic run. Drug launches were strong, investor sentiment was favorable, capital inflows were spiking, and falling interest rates were particularly supportive for unprofitable smaller-cap biotechs. Healthcare private equity deal activity, which had shown an

Blackstone has successfully closed a Life Sciences fund totaling $6.3 billion , marking it as the largest to date. This fund represents a substantial 40% increase over its 2020 predecessor, signifying an intensified strategic focus on biopharmaceutical investments. Key Strategic Implications: This significant capital raise underscores growing investor confidence within the life sciences sector. It further highlights the expanding role of private equity in funding critical d

The ability to make direct investments can be very attractive to family members and those running family office investment portfolios. It can mean investing in areas related to the wealth-creating activities of the family members, or areas in which they have developed a particular interest. Many family offices pursue direct investments with a goal of enhanced returns by avoiding the management fees and carried interest of fund investments, in addition to supporting the family

Capital is tight, and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures. recent delivery by Antoine Papiernik, Chairman & Managing Partner at Sofinnova Partners * "Even in uncertain times, life sciences remain at the core of what our societies need most. Large pharmaceutical companies depend on a steady flow of breakthrough ideas from biotechs, and that need keeps our ecosystem mo

' Looking Back & Forward '' Market landscape VC and M&A activity have declined in both total deal count and value over the past three years, while partnerships show fewer deals but higher total deal value. This shift represents a significant change in the investment landscape, as members at BROTHERS & Partners have identified the following investment trends: - Investment trends : Late-stage deals take the spotlight. Rare diseases, next-gen modalities, and AI/ ML lead the

Neurodegeneration Melatonin shows promise in Alzheimer's treatment by restoring circadian rhythms and reducing neurodegenerative symptoms, researchers have demonstrated in a groundbreaking study. A groundbreaking study conducted by researchers at Nanjing Pharmaceutical University has introduced an innovative therapeutic strategy for combating Alzheimer's disease , linking aging processes with neurodegenerative diseases. The researchers employed an AI-driven screening method

OrbiMed is a global healthcare investment firm that finances companies across all stages of the life sciences sector, from early-stage biotechs to large pharmaceutical enterprises. How would you describe the current investment climate for the biotech sector? Do you believe the difficult period the industry has faced in recent years is finally coming to an end? I think it’s an exciting time for the sector. It’s never easy to be a biotech investor, but over the last several mon

The geopolitical landscape is the key challenge that they face in their investment decision-making. The CIOs of British and mainland...

Paris is known for many things, from romance to art to world-beating croissants. But perhaps one of its lesser-known attributes is that...

PitchBook - European life sciences kicks off year with deluge of VC capital